Measures to quantify the abuse of prescription opioids: A review of data sources and metrics

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 12, 2014, Pages 1227-1237

  Secora, Alex M ^a   Dormitzer, Catherine M ^a   Staffa, Judy A ^a   Dal Pan, Gerald J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Abuse; Data sources; Diversion; Measurement; Metrics; Pharmacoepidemiology; Prescription opioid

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADDICTION; HUMAN; STANDARDS; STATISTICS; TRENDS;

ANALGESICS, OPIOID; HUMANS; STATISTICS AS TOPIC; SUBSTANCE-RELATED DISORDERS;

EID: 84913540600     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3711     Document Type: Review

References (61)

1. Wright C, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug and alcohol dependence 2006; 83: S68-S76.
2. Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug and alcohol review 2011; 30: 300-305.
3. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA 2011; 306: 2258-2259.
4. Cicero TJ, Surratt H, Inciardi JA, et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol and Drug Saf 2007; 16: 827-840.
5. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83: S4-S7.
6. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 618-627.
7. Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm reduction journal 2011; 8: 29.
8. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. Journal of pain & palliative care pharmacotherapy 2010; 24: 141-144.
9. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol and Drug Saf 2001; 10: 407-410.
10. U.S. Food and Drug Administration (FDA). Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. FDA CDER/CBER, Rockville; 2005
11. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. 2012 National Survey on Drug Use and Health: Sample Design Report (Prepared for the 2012 Methodological Resource Book). Prepared y Research Triangle Park (RTI) International; [January 2013].
12. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, and Office of Applied Studies. Redesigning an Ongoing National Houehold Survey: Methodological Issues, 2002; DHHS Publication No. SMA 03-3768.
13. Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clinical toxicology 2007; 45: 144-151.
14. Compton WM, Thomas YF, Conway KP, et al. Developments in the epidemiology of drug use and drug use disorders. The American journal of psychiatry 2005; 162: 1494-1502.
15. Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13: 401-435.
16. Smith MY, Woody G. Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options. Current psychiatry reports 2005; 7: 337-343.
17. U.S. Department of Health and Human Services, Substance Abuse and Mental health Services Administration, and Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network, 2009: Methodology Report; 2011.
18. Homenko H. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS). Health matrix 2012; 22: 273-313.
19. U.S. Department of Health and Human Services and Centers for Disease Control and Prevention. Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs-United States, 2004-2008. Morbidity and Mortality Weekly Report 2010; Volume 59, [Number 23]
20. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain medicine 2004; 5: 59-65.
21. Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug and alcohol dependence 2006; 82: 135-142.
22. Finklea KM, Agalman E, Acco LN. Prescription Drug Monitoring Programs, Congressional Research Service 2013; Report No. R42593 [Accessed 20 November 2012]
23. White AG, Birnbaum HG, Schiller M, et al. Analytic models to identify patients at risk for prescription opioid abuse. The American journal of managed care 2009; 15: 897-906.
24. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance-analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol and Drug Saf 2010; 19: 115-123.
25. Peirce GL, Smith MJ, Abate MA, et al. Doctor and pharmacy shopping for controlled substances. Medical care 2012; 50: 494-500.
26. Wilsey BL, Fishman SM, Gilson AM, et al. An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiol and Drug Saf 2011; 20: 1262-1268.
27. Cepeda MS, Fife D, Chow W, et al. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US. Drug safety 2012; 35: 325-334.
28. Cepeda MS, Fife D, Chow W, et al. Opioid shopping behavior: how often, how soon, which drugs, and what payment method. Journal of clinical pharmacology 2012: 1-6.
29. Bronstein AC, Spyker DA, Cantilena LR, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clinical toxicology 2011; 49: 910-941.
30. Goldman SA. Limitations and strengths of spontaneous reports data. Clinical therapeutics 1998; 20: C40-C44.
31. Hoppe-Roberts JM, Lloyd LM, Chyka PA. Poisoning mortality in the United States: comparison of national mortality statistics and poison control center reports. Annals of Emergency Medicine 2000; 35: 440-448.
32. Anderson B, Ke X, Klein-Shwartz W. Potential for erroneous interpretation of poisoning outcomes due to changes in National Poison Data System reporting. Clinical Toxicology 2010; 48: 745-749.
33. Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol and Drug Saf 2013; (wileyonlinelibrary.com) DOI: 10.1002/pds.3522.
34. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain medicine 2012; 13: 434-442.
35. Smith MY, Schneider MF, Wentz A, et al. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches. Clinical toxicology 2007; 45: 23-30.
36. Smith MY, Irish W, Wang J, et al. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers. Pharmacoepidemiol and Drug Saf 2008; 17: 1050-1059.
37. Bailey JE, Barton PL, Lezotte D, et al. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug and alcohol dependence 2006; 84: 182-187.
38. Cicero TJ, Kurtz SP, Surratt HL, et al. Multiple determinants of specific modes of prescription opioid diversion. Journal of drug issues 2011; 41: 283-304.
39. Cicero TJ, Dart RC, Inciardi JA, et al. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain medicine 2007; 8: 157-170.
40. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain medicine 2010; 11: 1078-1091.
41. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol and Drug Saf 2008; 17: 1142-1154.
42. Benneyan JC, Villapiano A, Katz N, et al. Illustration of a statistical process control approach to regional prescription opioid abuse surveillance. Journal of addiction medicine 2011; 5: 99-109.
43. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) State Instruction Manual: Admission Data with National Outcomes Measures (NOMS). Prepared by Synectics for Management Decisions, Arlington, VA.; [February 2010].
44. U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System (NFLIS). National Estimates Methodology, [September 2011].
45. Bachman JG, Lloyd DJ, O'Malley PM. Monitoring The Future (MTF): Questionnaire Responses from the Nation's High School Seniors, 2010. The University of Michigan: Survey Research Center & Institute for Social Research, 2011.
46. Executive Office of the President & Office of National Drug Control Policy. ADAM II: Arrestee Drug Abuse Monitoring Program II, 2011 Annual Report; [May 2012].
47. Department US. of Health and Human Services and Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief-United States, 1999-2010. Morbidity and Mortality Weekly Report 2012; 61: 493-497.
48. Walsh SL, Nuzzo PA, Lofwall MR, et al. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug and Alc Dep 2008; 98: 191-202.
49. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public health reports 1987; 102: 426-429.
50. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and alcohol dependence 2003; 69: 215-232.
51. Cicero TJ, Inciardi JA, Surratt H. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug and alcohol dependence 2007; 91: 115-120.
52. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol and Drug Saf 2005; 14: 851-859.
53. Woody GE, Senay EC, Geller A, et al. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug and alcohol dependence 2003; 72: 163-168.
54. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug and alcohol dependence 2003; 70: S97-105.
55. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug and alcohol dependence 1999; 57: 7-22.
56. Pierfitte C, Begaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? British journal of clinical pharmacology 1999; 47: 329-331.
57. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug safety 2003; 26: 159-186.
58. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain 2013; 14: 351-358.
59. Cassidy TA, DasMahapatra P, Black R, et al. Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation. Pain Medicine, published online [11 Dec 2013].
60. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycododne in 2010. American Pain Society 2013; 14: 1122-1130.
61. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138: 440.